September 29, 2021

AlzeCure Pharma - Introduction & Update

Martin Jönsson - CEO



Agenda

- Who we are
- Focus areas
- Pipeline & the science
 - Progress & goals in 2021





AlzeCure Pharma

- > Working in Alzheimer's Disease (AD) and Pain multi-billion markets / great unmet medical need
- > Founded in **2016**, out of a research foundation sponsored by Alzheimerfonden
- > Experienced team with extensive background within Pharma industry
- > Based at Novum Science Park, Karolinska Institute, Stockholm, Sweden
- > Three project platforms with multiple **small molecule** candidates
 - NeuroRestore[®] A novel first-in-class symptomatic treatment for cognitive disorders, e.g. AD
 - Alzstatin[®] An innovative disease-modifying treatment for AD
 - Painless Innovative projects for osteoarthritic and neuropathic pain
- Listed on Nasdaq First North Premier Growth Market since Nov. 2018 (Ticker: ALZCUR)
- Market cap: SEK 302m (Sept 27, 2021)
- Cash position: SEK 78m (Q2 2021 report)





Our Business Model

- We are a **Research & Development** company
- Research & develop through early clinical phase and then to out-license or partner on our projects
- Gain incomes through:
 - Upfront payments
 - Milestone payments
 - Royalties on sold products





A pipeline of small-molecule programs

- Multiple candidates increase chance of success

Platform	Candidate	Indication	Research phase	Preclinical phase	Phase I	Phase II	Phase III
NeuroRestore®	ACD856	Alzheimer's Disease, Sleep disorders, Traumatic brain injuries Parkinson's disease				Ongoing Fully funded Ph	
	ACD857	Alzheimer's Disease					
Alzstatin®	ACD679	Alzheimer's Disease					
	ACD680	Alzheimer's Disease					
PainLess	ACD440	Neuropathic Pain				Finalized & positive read-out Preparing for phase II filing	
	TrkA-NAM	Osteoarthritic Pain & other severe pain conditions					




Phase ongoing

Our primary Focus area


Alzheimer's Disease

- Costs the society more than oncology and cardiovascular diseases TOGETHER
- The patient population and costs will TRIPLE in the next 30 years





Tripling patient population – due to the aging population



- 50 million people worldwide live with dementia ...
- ... and doubling every 20 years
- Alzheimer's accounts for 60 70% of all dementia cases



8

Alzheimer's Disease - Progressive & lethal disorder with lack of available therapies

Pre-symptomatic Alzheimer's 10 - 20 years prior to symptoms

- In Pre-symptomatic Alzheimer's, Aβ amyloid pathology & plack is building up in the brain but there are no clinical symptoms
- There are no preventive treatments for this stage of Alzheimer's

No drugs available

Symptomatic Alzheimer's 7 - 10 years life expectancy

 The stage includes dying neurons in the brain which leads to speech problems, memory loss and dementia, and symptoms start manifesting



Very few drugs available - associated with low efficacy and severe side effects

HUGE UNMET MEDICAL NEED IN BOTH CATEGORIES





Enormous market potential

US sales \$17 billion



Aduhelm® projected annual sales **if only 5% of the Alzheimer's patients are treated** with the product.*


=> 2nd biggest selling product in the US.

*) Nature, June 8, 2021; Landmark Alzheimer's drug Approval..."



Progression of Alzheimer's Disease





Healthy Brain

Mild Alzheimer's Disease*


AlzeCure work to preserve the healthy brain




*) Indication of Aduhelm® (aducanumab)

Two Alzheimer's platforms - 1st-in-class properties & potential game-changers

TARGET TWO KEY AREAS WITH A HIGH UNMET MEDICAL NEED





NeuroRestore®

Improving Neuronal Function

Novel Oral Small Molecule




NeuroRestore®

- A cognitive enhancer



IZCUUIC

NeuroRestore[®] enhances neuronal function & cognitive capabilities




 AlzeCure's compounds act as enhancers of neurotrophin, e.g. BDNF/NGF signalling, and the broad effect profile in this specific biological pathway implies multiple possible indications, including Alzheimer's disease, but also e.g. Parkinson's disease, Traumatic Brain injury and Sleep disorders.




Alzheimer's Disease Modifier – Preventing or delay disease progression

ALZHEIMER'S DISEASE PROGRESSION




Ab-42 - main culprit in Alzheimer progression




found a way to limit Ab-42 clustering


Alzstatin modulates the enzyme and thereby limits the clustering effect





The Amyloid cascade - Generating toxic and damaging fragments, including plaques, damaging neurons and brain structures







Our second Focus area

Chronic Pain

- Suicide due to chronic pain is as common as due to depression
- Most common cause for sick leaves, creating misery & high societal costs
- Opioid crisis in the US is huge & reversing the mean average lifespan of Americans



Huge need for more efficacious and safer treatments



Our platform PAINLESS – Targeting unmet medical needs within pain



Neuropathic pain*

25 – 30 million patients

Project: ACD440



Osteoarthritis & severe pain conditions

> 300 million patients

Project: TrkA-NAM



*) Neuropathic pain = Pain initiated or caused by a primary lesion or dysfunction in the somatosensory nervous system

ACD440 – Novel VR1 antagonist in clinical phase targeting neuropathic pain

PROJECT OVERVIEW

Emanates from Big Pharma	 Approximately SEK 200m spent on project development Mode of action confirmed in several Phase 1 clinical trials Synthesized compound and formulation developed 				
VR1 – optimized	 The vanilloid receptor subtype 1 (VR1) is expressed in nociceptive sensory neurons 				
for local delivery	 VR1 is upregulated in the skin of patients with neuropathic pain 				
for local delivery	 Strong scientific support for peripheral/local treatment with VR1 antagonists 				
	 The trial was fully funded with existing funds 				
Phase 1b trial fully funded	 Trial with topical formulation has now ended 				
rany ranaca	Phase 1b study addressed both tolerability & efficacy – POSITIVE OUTCOMES				

Now preparing **filling for a phase II clinical trial**



Neuropathic pain - Fast growing market

- The most valuable segment within the pain indications
- Poorly served patients
- Huge demand for better drugs





The Neuropathic Pain market was valued at \$10,8 billion in 2020 globally and is forecast to reach \$25,2 billions by 2027, at a Compound Annual Growth Rate (CARG) of 12,9%

GlobalData, Global Pain Therapeutics Market Overview, May 2021



Key short-term milestones for 2021



Read-out of clinical 1b study Painless ACD440 in summer 2021



Read-out of clinical 1a SAD study NeuroRestore® ACD856 summer 2021



Start NeuroRestore® ACD856 1a MAD clinical study in second half 2021

Select CD for our pain project Painless TrkA-NAM in second half 2021

File phase 2a clinical study for Painless ACD440 second half 2021



Key investment highlights in AlzeCure



Targeting areas of huge unmet medical needs



Strong team with extensive experience and track record



Platforms with first-in-class properties and potential game-changers



Parallel investments in several candidates and potent follow-up programs



Multi-billion dollar market opportunities



Evolving into a phase II company



Karolinska Institutet Novum Science Park Hälsovägen 7, 141 57 Stockholm SWEDEN

www.alzecurepharma.com

